Skip to main content

Table 1 Biometric and hemodynamic parameters of hamsters with normal heart and heart failure

From: GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy

 Normal hamsters (J2N-n)PBS treatment (J2N-k)Low-dose liraglutide treatment (J2N-k)High-dose liraglutide treatment (J2N-k)
(n = 8)(n = 14)(n = 12)(n = 13)
Biometry
 Body weight, g120 ± 4.8111 ± 2.7113 ± 2.1107 ± 2.8
 Heart, g0.51 ± 0.220.63 ± 0.200.60 ± 0.020.72 ± 0.04
 Heart/BW, mg/g4.3 ± 0.05.7 ± 0.25.3 ± 0.36.7 ± 0.4*
 Lungs, g0.75 ± 0.030.74 ± 0.040.62 ± 0.020.85 ± 0.09
 Lungs/BW, mg/g5.8 ± 0.26.8 ± 0.45.5 ± 0.27.9 ± 0.9
Echocardiography
 HR, beats/min392 ± 18376 ± 13412 ± 17376 ± 19
 LVEDD, mm4.5 ± 0.17.5 ± 0.27.5 ± 0.27.4 ± 0.1
 LVESD, mm2.5 ± 0.16.6 ± 0.26.4 ± 0.26.3 ± 0.2
 LV ejection, %0.81 ± 0.010.31 ± 0.010.36 ± 0.020.35 ± 0.02
 LV FS, %0.45 ± 0.010.13 ± 0.010.15 ± 0.010.15 ± 0.01
 LV AW, mm0.95 ± 0.020.81 ± 0.020.72 ± 0.02*0.67 ± 0.01*
 LV PW, mm1.02 ± 0.020.84 ± 0.020.81 ± 0.020.79 ± 0.02
Intracardiac pressure
 Positive dP/dt, mmHg/s5512 ± 5393566 ± 2353100 ± 3102501 ± 290*
 Negative dP/dt, mmHg/s− 4119 ± 543− 2669 ± 143− 2425 ± 281− 1700 ± 171*
 EDP, mmHg8.65 ± 1.78.71 ± 2.412.5 ± 4.313.8 ± 2.8
 Max pressure, mmHg132 ± 1380.6 ± 4.281.9 ± 1466.1 ± 5.5
 Min pressure, mmHg4.5 ± 2.06.1 ± 2.09.3 ± 3.09.4 ± 2.0
  1. All values are expressed as mean ± SEM
  2. HR heart rate, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, FS fractional shortening, AW anterior wall, PW posterior wall, EDP end-diastolic pressure, FFA free fatty acid
  3. Liraglutide treatment groups compared with the PBS treatment group by the step-down method. *P < 0.05